Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Creative Medical Technology Holdings (CELZ) over the last 16 years, with Q1 2025 value amounting to $3.4 million.

  • Creative Medical Technology Holdings' Cash from Financing Activities rose 415092.03% to $3.4 million in Q1 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 206172.98%. This contributed to the annual value of $1.5 million for FY2024, which is 63686.11% up from last year.
  • According to the latest figures from Q1 2025, Creative Medical Technology Holdings' Cash from Financing Activities is $3.4 million, which was up 415092.03% from $1.6 million recorded in Q4 2024.
  • In the past 5 years, Creative Medical Technology Holdings' Cash from Financing Activities registered a high of $15.5 million during Q2 2022, and its lowest value of -$191780.0 during Q3 2023.
  • In the last 5 years, Creative Medical Technology Holdings' Cash from Financing Activities had a median value of $105593.0 in 2021 and averaged $2.5 million.
  • Per our database at Business Quant, Creative Medical Technology Holdings' Cash from Financing Activities surged by 1455269.48% in 2022 and then crashed by 159826666.67% in 2023.
  • Creative Medical Technology Holdings' Cash from Financing Activities (Quarter) stood at $9.3 million in 2021, then crashed by 100.0% to $12.0 in 2022, then crashed by 659866.67% to -$79172.0 in 2023, then skyrocketed by 2158.18% to $1.6 million in 2024, then skyrocketed by 105.83% to $3.4 million in 2025.
  • Its Cash from Financing Activities stands at $3.4 million for Q1 2025, versus $1.6 million for Q4 2024 and -$25450.0 for Q3 2024.